The potential of A. Muricata Bioactive Compounds to Inhibit HIF1α Expression Via Disruption of Tyrosine Kinase Receptor Activity: an In Silico Study

Firli Rahmah Primula Dewi, Rasyidah Fauzia Ahmar, Na’ilah Insani Alifiyah, Nadia Shoukat, Sri Puji Astuti Wahyuningsih

Department of Biology, Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia

Corresponding author: Firli Rahmah Primula Dewi, PhD. Faculty of Science and Technology, Universitas Airlangga. Address: Jl. Ir. Dr. Soekarno, Mulyorejo Surabaya, Indonesia. Phone: +62813556596292. E-mail: firli.rahmah@fst.unair.ac.id. ORCID ID: https://orcid.org/0000-0002-7813-8435.

doi: 10.5455/aim.2021.29.176-181

1. BACKGROUND
Cancer is a complex and devastating disease leading to millions of death every year (1-3). Due to the disorganized and lack of structural integrity of blood vessel in tumor, some tumor areas experienced inadequate perfusion and transient hypoxia. Hypoxia inducible factor-1 (HIF1) have been reported to be involved in the response to hypoxic stress (4). HIF1 consist of subunit α and subunit β. HIF1α is upregulated in hypoxic tumor cells and actsuates the transcription of target genes, allowing cellular adaptation to hypoxia and tumor angiogenesis (5-6). The main signaling pathways involved in the regulation of HIF1α expression is phosphoinositide 3-kinases (PI3K)/Akt signaling pathway (7). PI3K is activated by the binding of a variety of growth factors to their receptor following by activation of its downstream signaling such as Akt and mTOR signaling pathways (8).

Currently, the main cancer treatment are surgery, radiation-based therapy, chemotherapy, gene therapy, and/or hormonal therapy (9-10). However, these treatments mostly affect both normal and tumor cells and therefore induce side effects such as suppression of bone marrow, hair loss and cardiac toxicity (11). Hence, the identification of new anti-cancer agents with higher selectivity with little or no side effects is a pressing goal.

The use of anti-inflammatory herbal products for cancer prevention and therapy is an interesting area of study in the last decades. Graviola (Annona muricata) is one of the trop-
ical plant that have been studied due to their anti-inflammatory and anti-cancer effects (9, 12). Many studies have linked *A. muricata* derived compounds as well as its crude extracts to a variety of anticancer effects including induction of apoptosis (13) and inhibition of proliferation (14) on a variety of cancer cell lines, including breast (15) and colorectal cancer (16). Latest study reported the anti-angiogenic potential of *A. muricata* crude extract on chick chorioallantoic angiogenic (CAM) assays in dose dependent manner (17). However, to date, the study exploring the potency of single bioactive compounds of *A. muricata* are very limited, hence an in silico study is needed for preliminary screening of the involvement of *A. muricata* bioactive compounds during angiogenesis.

2. OBJECTIVE

The aim of the study was to investigate the potential of the bioactive compounds of *A. muricata* in regulating angiogenesis process, primarily by the regulation of HIF1α expression by *in silico* study.

3. MATERIALS AND METHODS

**Bioactive Compounds Preparation**

Nineteen of *A. muricata* bioactive compounds were analyzed in this study, including annomuricin E (CID 3083520), annonacin (CID 354398), muricoreacin (CID 44559048), genistein (CID 5280961), catechin (CID 9064), epicatechin (CID 72276), argentinine (CID 10085878), asimilobine (CID 160875), ancone (CID 160597), coquarine (CID 160487), isolaurine (CID 1231076), reticuline (CID 439653), xylidine (CID 160503), annonoxecin (CID 10054746), muricoreacin C (CID 10258454), squamocin (CID 441612).

**Biological Activity Prediction**

Biological activity of each active compounds was predicted using the Prediction of Activity Spectra for Substances (PASS) Server (http://www.pharmaexpert.ru/passsonline/) (18). The compounds were predicted for human intestinal absorption (HIA) for evaluating the potency for oral use by using Laboratory of Molecular Modeling and Design webserver (http://lmmd.ecust.edu.cn). The lethal dose (LD50) of each compound was also evaluated to predict the lethal dose when applied *in vivo* in rat model animal (19).

**Protein Target and Pathway Analysis**

The protein target of the bioactive compounds was evaluated using hit identification and target prediction using HITPICK Server (http://mips.helmholtz-muenchen.de/hitpick/). Analysis of the molecular pathway prediction was performed using STITCH webserver (http://stitch.embl.de/).

**Obtaining the amino acids sequences of IFNγ, IFNγR, IL-6, IL6R, LPS and TLR4**

The amino acid sequences of *Homo sapiens* interferon (IFN)-γ (GI: 56786138), IFNγR (GI: 124474), IL-6 (GI: 4261586), IL-6R subunit α (GI: 124343), lipopolysaccharida (LPS) *Sinorhizobium melliti* (GI: 152264), and TLR-4 (GI: 6175873) were obtained from NCBI database (https://www.ncbi.nlm.nih.gov).

**3D modeling of IFNγ, IFNγR, IL-6, IL6R, LPS and TLR4 protein structure**

The 3D structure of IFNγ, IFNγR, IL-6, IL6R, LPS and TLR4 proteins was predicted by using homology modeling method provided by SWISS-MODEL web server (https://swissmodel.expasy.org) (20).

**Protein-ligand and protein-protein docking,**

Docking of the active compounds of *A. muricata* with IFNγ, IFNγR, IL-6, IL6R, LPS and TLR4 protein was performed by using SwissDock webserver (http://www.swissdock.ch). The protein-protein docking simulation was then performed using ClusPro Webserver (https://cluspro.org) (21).

**Visualization and Analysis of the Interactions**

The results of the docking were visualized using UCSF Chimera software (https://www.cgl.ucsf.edu/chimera), and the ligand bond interactions between bioactive compounds and protein was analyzed using LigPlot+ software (https://www.ebi.ac.uk/thornton-srv/software/LigPlus).

4. RESULTS

**The Biological Activity of Annona muricata active compounds**

HIF1α expression and activity plays a crucial role in the angiogenesis, so we first analyzed the potency of the bioactive compounds of *A. muricata* in repressing HIF1α expression. The screening was based on the Pa score, which if the score of Pa is 0.3 means that the bioactive compound has minimum potency for the specific activity. And if the score of Pa is more than 0.7, the laboratory experiments result will be similar to computational prediction results. There are 5 compounds that have a Pa score above 0.7 in the activity of HIF1α expression inhibitor. However, we screened the best three compounds that have high probability, including kaempferol (Pa: 0.969), genistein (Pa: 0.939), xylidine (Pa: 0.922), genistein (Pa: 0.914), glycitein (Pa: 0.914) and genistein (Pa: 0.914).

| Active compounds | Pa score | HIA+ | LD50 (mol/kg) |
|------------------|----------|------|---------------|
| Kaempferol       | 0.969    | 0.986| 3.08          |
| Genistein        | 0.939    | 0.988| 3.30          |
| Glycitein        | 0.914    | 0.989| 2.82          |
| Catechin         | 0.883    | 0.965| 1.87          |
| Epicatechin      | 0.883    | 0.965| 1.87          |
| Argentinine      | 0.589    | 0.989| 2.69          |
| Squamocin        | 0.539    | 0.989| 2.79          |
| Annomuricin E    | 0.494    | 0.916| 2.36          |
| Annonacin        | 0.494    | 0.964| 2.42          |
| Asimilobine      | 0.481    | 0.990| 2.61          |
| Annohexocin      | 0.473    | 0.937| 2.61          |
| Coquarine        | 0.472    | 0.984| 2.52          |
| Reticuline       | 0.460    | 0.918| 2.69          |
| Murihexocin C    | 0.432    | 0.916| 2.36          |
| Muricoreacin C   | 0.432    | 0.916| 2.36          |
| Isoxalureline    | 0.347    | 0.994| 2.68          |
| Xylopine         | 0.341    | 0.992| 2.69          |
| Analone          | 0.261    | 0.995| 2.78          |

Table 1. *A. muricata* bioactive compounds based on Pa Score, HIA, and LD50 analysis
HIA analysis was performed for evaluating the pharmacokinetics properties of the bioactive compounds. Among 19 bioactive compounds of *A. muricata* analyzed, 95% of them have HIA score above 0.9. This means that the extract can be easily absorbed in the human intestine. The lethal dose parameter is important information before conducting *in vivo* experiment. Lethal dose prediction analysis showed that all of the compounds have LD50 below 3.5 mol/kg (Table 1).
Annona muricata bioactive compounds as anti-angiogenic factor via PI3K/Akt signaling pathway

The biological activity prediction showed that three active compounds of A. muricata possesses as anti-angiogenic factor by inhibit HIF1α expression. To investigate the pathway behind this process, we performed molecular pathway prediction analysis. The result showed that glycitein, genistein, and kaempferol could affect several proteins including RAC-alpha serine/threonine-protein kinase (AKT1), androgen receptor (AR), and forhead box O3 (FOXO3). As previously mentioned that the main signaling pathways involved in the regulation of HIF1α expression is PI3K/Akt pathway, here we confirmed that glycitein, genistein, and kaempferol have the ability to inhibit Akt1 protein (score: 0.960). In addition, the three compounds also can inhibit Fcho-3 transcription activator, another downstream target of Akt1 signaling responsible for triggering apoptosis in the absence of survival factors (Figure 1).

In order to further investigate the effect of kaempferol, genistein, and glycitein binding to IFNyR, IL-6R, and TLR4, next we performed the docking of ligand and its receptor, and also ligand with its receptor that already binds by kaempferol, genistein, or glycitein. The result in Table 2 showed that the binding free energy value (weighted score) for IFNy–IFNyR interaction is -783.2 kcal/mol, with the lowest energy in that cluster is -908.2 kcal/mol. There are 13 hydrogen bonds and 2 hydrophobic bonds formed between IFNy–IFNyR. This result showed that IFNy-IFNy is not the target molecules of kaempferol, genistein, or glycitein, because the active compounds is not capable to disrupt IFNy-IFNy interaction.

The docking result between IL6 and its receptor showed that the binding free energy for their interaction is -624.1 kcal/mol with the lowest binding energy in that cluster is -734.9 kcal/mol. There are 36 hydrogen bonds and 2 hydrophobic bonds that formed in the interaction. The binding of kaempferol, genistein, or glycitein to IL6R slightly reduce the binding free energy (-628.1 kcal/mol) but increase the lowest energy (-731.2 kcal/mol) for IL6γ–IL6R interaction. It also significantly reduced the number of hydrogen and hydrophobic bonds formed between IL6–IL6R (Table 2). These results showed that IL6R

| Ligand - Receptor | Weighted score (kcal/mol) | Interaction (bond) | Residue (Ligand – Receptor) |
|-------------------|---------------------------|--------------------|-----------------------------|
| IFNy - IFNy receptor (IFNyR) Center: -783.2 | Hydrogen | Arg130-Glu197; Asn127-Val152; His134-Gln199; Ser135-Glu197; Gly161-Glu197; Lys153-Glu164; Arg160-Asp155; Arg160-Tyr161; Lys151-Asp155; Gly150-Asp160; Lys148-Glu158; Lys148-Val159; Lys148-Gln157. Lys151-Glu156. |
| Lowest: -908.2 | Hydrophobic | |
| IFNy - IFNyR, kaempferol; IFNy - IFNyR, genistein; IFNy - IFNyR, glycitein Center: 839.8 | Hydrogen | Arg130-Glu197; Asn127-Val152; His134-Gln199; Ser135-Glu197; Gly161-Glu197; Met177-Glu197; Phe159-Glu197; Arg160-Asp155; Arg160-Tyr161; Lys151-Asp155; Lys153-Pro163; Gln150-Tyr161; Gln150-Val159; Lys148-Gln157; Lys148-Asp89. His134-Asp144; Lys153-Glu164; Lys148-Glu156. Lys148-Glu158. |
| Lowest: -910.8 | Hydrophobic | |
| IL6 – IL6 receptor (IL6R) Center: -624.1 | Hydrogen | His164-Glu152; Gin155-Glu152; Asp168-Glu144; Asp168-Arg141; Thr170-Arg141; Asp162-Lys156; Asp162-Arg52; Lys159-Lys157; Lys159-Lys156; Ala158-Lys156; Leu161-Lys156; Leu161-Arg52; Gin144-Asp148; Arg141-Asp148; Arg141-Asp168; Arg141-Asp168. Asn160-Arg52; Asn160-Arg52; Asn131-Thr170; Gin130-Thr170; Gin132-Ile164; Gin152-Ile164; Gin152-Gln155; Lys157-Lys159; Lys156-Lys159; Lys156-Ala158; Lys156-Asp162; Arg52-Asn160; Arg52-Leu161; Arg52-Asp162; Arg52-Lys159; Asn88-Lys159; Asn88-Arg151; Asn88-Arg23; Leu85-Arg23; Leu85-Arg23; Glu87-Arg23; Glu87-Arg23. Asp168-Arg141; Glu87-Arg23. |
| Lowest: -734.9 | Hydrophobic | |
| IL6 – IL6R, kaempferol; IL6 – IL6R, genistein; IL6 – IL6R, glycitein Center: -628.1 | Hydrogen | Asn88-Arg151; Asn88-Arg151; Asn88-Arg23; Leu85-Arg23; Leu85-Arg23; Glu85-Arg23. |
| Lowest: -731.2 | Hydrophobic | Glu87-Arg23. |
| LPS – TLR4 Center: -890.9 | Hydrogen | Glu402-Arg264; Glu244-His456; Asp245-His529; Arg256-Gln505; Arg256-His529; Gin129-Lys477; Tyr257-Asp580; Asn196-Glu42; Lys289-Gly40; Val250-Glu578; Arg91-Asp181; Arg91-Asp181; Arg91-Asn156; Gin160-Ser360; Arg131-Asp550; Gin120-Asn58; Gin120-Thr37; Met251-Arg606; Ser385-Glu266; Ser385-Asn265; Asn177-Arg606. Glu402-Arg264; Lys134-Glu603. |
| Lowest: -1217.2 | Hydrophobic | Glu87-Arg23. |
| LPS – TLR4, kaempferol; LPS – TLR4, genistein; LPS – TLR4, glycitein Center: -841.8 | Hydrogen | Lys139-Gln547; Ser179-Arg606; Asp177-Arg606; Asp177-Arg606; Asp177-Arg606; Asp177-Arg606; Asp177-Arg606; Asp177-Arg606; Arg131-Ser52; Arg131-Asp550; Thr105-Gln523; Thr105-Gln523; Asn104-Thr499; Asn104-Glu474; Thr105-Glu474; Ser385-Asn265; Ser385-Arg234; Ser385-Arg234; Leu836-Arg234; Thr198-Glu42; Thr198-Glu42; Asn196-Glu42; Val81-Arg382; Lys85-Asp405; Lys85-Tyr403; Lys85-Arg382; His82-Glu430; His82-Arg382; His161-Lys362. Lys134-Asp550; Glu402-Arg264; Lys85-Asp379. |
| Lowest: -1199.3 | Hydrophobic | |

Table 2. The docking result of tyrosine kinase receptor with their respective ligand in the absence or presence of kaempferol, genistein and glycitein
was presumed to be the target molecules of kaempferol, genistein, or glycitein, because the active compounds was be able to disrupt IL6-IL6R interaction.

The last docking analysis was performed between LPS from Sinorhizobium meliloti bacteria to TLR4. The result showed that the binding free energy for their interaction is -890.9 kcal/mol with the lowest binding energy in that cluster is -1217.2 kcal/mol. There are 21 hydrogen bonds and 2 hydrophobic bonds that formed in the interaction. The binding of kaempferol, genistein, or glycitein to TLR4 significantly increased the binding free energy (-841.8 kcal/mol) as well as the lowest energy (-1199.3 kcal/mol) for LPS–TLR4 interaction (Table 2). These results showed that TLR4 was presumed to be the target molecules of kaempferol, genistein, or glycitein, because the active compounds was be able to disrupt LPS–TLR4 interaction.

**DISCUSSION**

HIF1α is the key factor in regulating angiogenesis process through its activity as transcription factor of several angiogenic factors. HIF-1α overexpression is associated with treatment failure and increased mortality. Several studies reported that HIF1α was overexpressed in common cancers (22) and associated with vascular endothelial growth factor (VEGF) expression and vascularization (23). Due to its significant role in regulating angiogenesis and metastasis process, HIF1α often targeted as therapeutics target for cancer (24). In this study, we found that kaempferol, genistein, and glycitein has the potential to inhibit HIF1α expression (Table 1).

HIF-1α protein synthesis is regulated by activation of the PI3K/Akt and mitogen-activated protein kinase (MAPK) pathways. These pathways can be activated by signaling via receptor tyrosine kinases, non-receptor tyrosine kinases or G-protein-coupled receptors. We analyzed three tyrosine kinase receptors which are the upstream of PI3K/Akt signaling pathway, including IFNγR, IL-6R, and TLR4R. We found that kaempferol, genistein, and glycitein might affect IL6 – IL6R binding as well as LPS – TLR4, but not IFNγ–IFNγR binding (Table 2). Previous study reported that kaempferol inhibits angiogenic ability by targeting VEGF receptor-2 and downregulating the PI3K/AKT and extracellular signal-regulated kinase (ERK) pathways in VEGF-stimulated human umbilical vein endothelial cells (25). Another study reported that genistein was found to inhibit angiogenesis through regulation of multiple pathways, such as PI3K/Akt and ERK1/2 signaling pathways (26). Most of the previous studies that reported about these bioactive compounds was focused only on the pathways affected, but did not explain how the bioactive compounds act. Here we are the first to reported that kaempferol, genistein, and glycitein affect PI3K/Akt signaling pathway due to their ability to disrupt IL6 – IL6R and LPS – TLR4 interaction.

**5. CONCLUSION**

There are 3 bioactive compounds of A. muricata with the ability to inhibit HIF-1α expression, including kaempferol, genistein, and glycitein. Based on the silico analysis in this study, we found that kaempferol, genistein, and glycitein inhibit HIF-1α expression through the disruption of IL6R and TLR4 and their respective ligands interaction.

- **Author’s contribution:** F.R.P.D has a major role in the designing and data collection of this work. R.F.A, N.I.A, N.S and S.P.A.W had a part in data analysis and article preparing for drafting.
- **Conflict of Interest:** There are no conflicts of interest.
- **Financial Support:** This work was funded by Hibah Riset Mandat, Universitas Airlangga, Indonesia (grant number: 390/UN3.14/PT/2020).

**REFERENCES**

1. Hyndman IJ. 2016. Review: the Contribution of both Nature and Nurture to Carcinogenesis and Progression in Solid Tumors. Cancer Microenvironment. 2016; 9:63-69.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646–674.
3. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti A, Batra SK. Targeting the EGF signaling pathway in cancer therapy. Expert Opin Ther. Targets. 2012; 16(1): 15-31.
4. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 1985; 2000(88): 1474-1480.
5. Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, Wells M, Lewis CE. Expression of HIF-1 alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol. 2002; 196:204–212.
6. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE. Ex-expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol. 2000; 192:150–158.
7. Stiehl DP, Jelkman W, Wenger RH, Hellwig-Burgel T. Normoxic induction of the hypoxia-inducible factor 1 alpha by insulin and interleukin-1 beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett. 2002; 512:157–162.
8. Xu F, Na L, Li Y, Chen L. Roles of the PI3K/AKT/mTOR signaling pathways in neurodegenerative diseases and tumours. Cell & Bioscience. 2020; 10: 54.
9. Rady I, Bloch MB, Chamcheu RCN, Mbeumi SB, Anwar MR, Mohamed H, Babatunde AS, Kulliate JR, Nouhissi FK, El Sayed KA, Whitfield GK, Chamcheu JC. Anticancer Properties of Graviola (Annona muricata): A Comprehensive Mechanistic Review. Oxidative Medicine and Cellular Longevity. 2018; 2018: 1826170.
10. Cunningham D, Okines AF and Ashley S: Capecitabine and oxaliplatin for advanced esophageal cancer. N Engl J Med. 2010; 362: 858-859.
11. Nussbaumer S, Bonnabry P, Veuthey JL, and Fleury-Souverain S. Analysis of anticancer drugs: a review. Talanta. 2011; 85(5): 2265–2289.
12. Wahab SMA, Jantan I, Haque MA, Arshad L. Exploring the Leaves of Annona muricata L. as a Source of Potential Anti-inflammatorv and Anticancer Agents. Frontiers in Pharmacology. 2018; 9:661.
13. Ezirim AU, Okochi VI, James AB, Adesebi OA, Ogunnosoo S and Odegeb OE. Induction of apoptosis in myelogenous leukemia k562 cells by ethanolic leaf extract of Annona muricata L. Global Journal of Research on Medicinal Plants & Indigenous Medicine. 2013; 2(3):142–151.
14. Asare GA, Afriyie D, Ngala RA, Abutiate H, Doku D, Mahmood SA, Rahman H. Antiproliferative activity of aqueous leaf ex-
tract of Annona muricata L. on the prostate, BPH-1 cells, and some target genes. Integrative Cancer Therapies. 2014; 14(1): 65–74.

15. Dai Y, Hogan S, Schmelz EM, Ju YH, Canning C, Zhou K. Selective growth inhibition of human breast cancer cells by graviola fruit extract in vitro and in vivo involving downregulation of EGFR expression. Nutrition and Cancer. 2011; 63(5): 795–801.

16. Moghadamtousi SZ, Karimian H, Rouhollahi E, Paydar M, Fadaeinasab M, Kadir HA. Annona muricata leaves induce G1 cell cycle arrest and apoptosis through mitochondria-mediated pathway in human HCT-116 and HT-29 colon cancer cells. Journal of Ethnopharmacology. 2014; 156: 277–289.

17. Gallego RP & Teves FG. Angiogenesis modulatory activity of SC-CO2 leaf extract of guyabano (Annona muricata Linn.) using chick embryo chorioallantoic membrane assay. AAB Bioflux. 2015; 7(3): 206-216.

18. Goel RK, Singh D, Lagunin A, Poroikov V. PASS-assisted exploration of new therapeutic potential of natural products. Med Chem Res. 2010; 20:1509-14.

19. Feixiong C, Weihua L, Yadi Z, Jie S, Zengrui W, Guixia V, Philip L, Yun T. admetSAR: a comprehensive source and free tool for evaluating chemical ADMET properties. J. Chem. Inf. Model. 2012; 52(11): 3099-3105.

20. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006; 22(2):195–201.

21. Desta IT, Porter KA, Xia B, Kozakov D, Vajda S. Performance and Its Limits in Rigid Body Protein-Protein Docking. Structure. 2020; 28 (9):1071-1081.

22. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000; 157:411–421.

23. Bos R, Zhong H, Hanrahan CF, Mommens EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001; 93:309–314.

24. Semenza GL. Targeting HIF-1 for cancer therapy. Nature reviews. Cancer. 2003 3(10): 721-732

25. Chin HK, Horng CT, Liu YS, Lu CC, Su CY, Chen PS, Chiu HY, Tsai FJ, Shieh PC, Yang JS. Kaempferol inhibits angiogenic ability by targeting VEGF receptor-2 and downregulating the PI3K/AKT, MEK and ERK pathways in VEGF-stimulated human umbilical vein endothelial cells. Oncol Rep. 2018; 39(5):2351-2357.

26. Varinska L, Gal P, Mojzisova G, Mirossay L, Mojzis J. Soy and Breast Cancer: Focus on Angiogenesis. Int J Mol Sci. 2015; 16(5): 11728–11749.